State of Alaska Department of Revenue Trims Stock Holdings in Hims & Hers Health, Inc. $HIMS

State of Alaska Department of Revenue lessened its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,020 shares of the company’s stock after selling 365 shares during the quarter. State of Alaska Department of Revenue’s holdings in Hims & Hers Health were worth $1,097,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ST Germain D J Co. Inc. purchased a new stake in shares of Hims & Hers Health in the second quarter valued at $133,000. Dakota Wealth Management purchased a new stake in Hims & Hers Health in the 2nd quarter valued at about $354,000. Fifth Third Bancorp increased its stake in shares of Hims & Hers Health by 58.8% during the 2nd quarter. Fifth Third Bancorp now owns 2,448 shares of the company’s stock valued at $122,000 after acquiring an additional 906 shares during the last quarter. Occidental Asset Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth about $305,000. Finally, AdvisorNet Financial Inc boosted its position in shares of Hims & Hers Health by 127.1% in the second quarter. AdvisorNet Financial Inc now owns 1,340 shares of the company’s stock worth $67,000 after acquiring an additional 750 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Michael Chi sold 2,100 shares of the stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $56.52, for a total value of $118,692.00. Following the completion of the transaction, the insider owned 291,439 shares in the company, valued at $16,472,132.28. This represents a 0.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 85,000 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $60.20, for a total transaction of $5,117,000.00. Following the sale, the chief financial officer owned 70,232 shares in the company, valued at $4,227,966.40. This trade represents a 54.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,611,146 shares of company stock valued at $83,026,206. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of several research reports. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research note on Friday, September 12th. Morgan Stanley reissued an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Truist Financial cut their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Zacks Research lowered Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Trading Down 9.1%

NYSE HIMS opened at $52.61 on Monday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a one year low of $16.69 and a one year high of $72.98. The company has a 50-day simple moving average of $51.47 and a 200-day simple moving average of $47.35. The firm has a market capitalization of $11.89 billion, a PE ratio of 65.77, a price-to-earnings-growth ratio of 3.55 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business’s revenue was up 72.6% compared to the same quarter last year. During the same period last year, the firm posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.